US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Landcadia Holdings IV Inc

10.54

0.0000

Volume:- -

Turnover:- -

Market Cap:142.91M

PE:103.68

High:10.54

Open:10.54

Low:10.54

Close:10.54

52wk High:10.54

52wk Low:10.54

Shares:13.56M

Float Shares:1.06M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1017

EPS(LYR):0.3860

ROE:--

ROA:-0.31%

PB:-24.43

PE(LYR):27.31

Loading ...

Overview Company News Filings

Bureau Veritas Showcases Three Key Net-Zero Transformation Solutions at Energy Taiwan

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Envision Energy Earns "Green Passport" EPD, Raising the Benchmark for Sustainable Wind Turbines

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Press Release: Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Press Release: Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LCA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LCA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LCA\",,,,,undefined,":{"symbol":"LCA","market":"US","secType":"STK","nameCN":"Landcadia Holdings IV Inc","latestPrice":10.54,"timestamp":1761854400000,"preClose":10.54,"halted":0,"volume":0,"delay":0,"floatShares":1058523,"shares":13558523,"eps":0.101663,"marketStatus":"Closed","change":0,"latestTime":"10-30 16:00:00 EDT","open":10.54,"high":10.54,"low":10.54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.101663,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1761897600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.54,"volumeRatio":0,"impliedVol":1.24,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LCA\",,,,,undefined,":{"symbol":"LCA","floatShares":1058523,"roa":"-0.31%","roe":"--","lyrEps":0.385996,"shares":13558523,"dividePrice":0,"high":10.54,"amplitude":0,"preClose":10.54,"low":10.54,"week52Low":10.54,"pbRate":"-24.43","week52High":10.54,"institutionHeld":0,"latestPrice":10.54,"eps":0.101663,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.101663,"open":10.54,"prevYearClose":10.54,"prevWeekClose":10.54,"prevMonthClose":10.54,"prevQuarterClose":10.54,"fiveDayClose":10.54,"twentyDayClose":10.54,"sixtyDayClose":10.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LCA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-28","symbol":"LCA","reason":null,"defaultRemindTime":1709130600000,"announcedDate":"2024-02-15","type":"delisting","dateTimestamp":1709096400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LCA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LCA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LCA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LCA","date":"2024-02-28","current":103.67587,"percent":0.59733,"low":11.488324,"twenty":30.050032,"median":45.140258,"eighty":66.415048,"high":224.854989,"avg":50.102288,"sd":30.317802,"marketCap":142906832},"quantilePoints":[{"date":"2020-10-30","current":46.748028,"twenty":28.967264,"median":36.954567,"eighty":53.722532,"marketCap":116340929},{"date":"2020-11-06","current":50.66883,"twenty":29.711336,"median":37.029159,"eighty":53.534032,"marketCap":126098555},{"date":"2020-11-13","current":117.235104,"twenty":32.659002,"median":37.195559,"eighty":53.534032,"marketCap":125109083},{"date":"2020-11-20","current":127.732453,"twenty":33.025314,"median":37.403191,"eighty":54.589633,"marketCap":136311476},{"date":"2020-11-27","current":176.426041,"twenty":33.483204,"median":37.919013,"eighty":55.720633,"marketCap":188275520},{"date":"2020-12-04","current":206.242042,"twenty":33.626294,"median":39.349919,"eighty":57.190934,"marketCap":220094082},{"date":"2020-12-11","current":195.480054,"twenty":33.941094,"median":40.294317,"eighty":59.716836,"marketCap":208609276},{"date":"2020-12-18","current":206.77132,"twenty":34.084184,"median":41.138551,"eighty":61.828037,"marketCap":220658909},{"date":"2020-12-24","current":224.854989,"twenty":34.656546,"median":41.496279,"eighty":63.916618,"marketCap":239957150},{"date":"2020-12-28","current":224.854989,"twenty":34.799637,"median":41.639369,"eighty":66.238939,"marketCap":239957150},{"date":"2021-03-26","current":67.434726,"twenty":34.822532,"median":44.259826,"eighty":66.87984,"marketCap":620000000},{"date":"2021-04-01","current":67.638662,"twenty":34.862598,"median":45.767827,"eighty":67.342317,"marketCap":621875000},{"date":"2021-04-09","current":67.910576,"twenty":34.954175,"median":46.295628,"eighty":67.665854,"marketCap":624375000},{"date":"2021-04-16","current":68.114512,"twenty":35.12016,"median":46.790631,"eighty":67.835015,"marketCap":626250000},{"date":"2021-04-23","current":67.978555,"twenty":35.320487,"median":47.879029,"eighty":67.947013,"marketCap":625000000},{"date":"2021-04-30","current":67.978555,"twenty":35.45213,"median":49.123129,"eighty":67.978555,"marketCap":625000000},{"date":"2021-05-07","current":67.842598,"twenty":35.486472,"median":50.06563,"eighty":67.978555,"marketCap":623750000},{"date":"2021-05-14","current":68.046533,"twenty":35.572327,"median":50.51803,"eighty":67.978555,"marketCap":625625000},{"date":"2021-05-21","current":65.39537,"twenty":35.938639,"median":50.78193,"eighty":67.978555,"marketCap":601250000},{"date":"2021-05-28","current":67.570684,"twenty":36.230544,"median":51.083531,"eighty":67.978555,"marketCap":621250000},{"date":"2021-06-04","current":67.638662,"twenty":36.310674,"median":51.837531,"eighty":67.978555,"marketCap":621875000},{"date":"2021-06-11","current":66.143134,"twenty":36.394254,"median":52.459581,"eighty":67.978555,"marketCap":608125000},{"date":"2021-06-18","current":66.483027,"twenty":36.512995,"median":53.157032,"eighty":67.978555,"marketCap":611250000},{"date":"2021-06-25","current":67.026855,"twenty":36.610243,"median":53.477482,"eighty":67.978555,"marketCap":616250000},{"date":"2021-07-02","current":66.279091,"twenty":36.655127,"median":54.174932,"eighty":67.978555,"marketCap":609375000},{"date":"2021-07-09","current":65.939198,"twenty":36.670088,"median":54.665033,"eighty":67.978555,"marketCap":606250000},{"date":"2021-07-16","current":66.007177,"twenty":36.737414,"median":55.362483,"eighty":67.972981,"marketCap":606875000},{"date":"2021-07-23","current":66.279091,"twenty":36.767336,"median":56.851634,"eighty":67.94946,"marketCap":609375000},{"date":"2021-07-30","current":65.939198,"twenty":36.767336,"median":57.247484,"eighty":67.937768,"marketCap":606250000},{"date":"2021-08-06","current":65.938518,"twenty":36.774817,"median":58.284235,"eighty":67.910576,"marketCap":606243750},{"date":"2021-08-13","current":65.939198,"twenty":36.812221,"median":60.546236,"eighty":67.910576,"marketCap":606250000},{"date":"2021-08-20","current":65.599305,"twenty":36.842143,"median":61.828037,"eighty":67.89698,"marketCap":603125000},{"date":"2021-08-27","current":65.905209,"twenty":36.842143,"median":63.147538,"eighty":67.842598,"marketCap":605937500},{"date":"2021-09-03","current":66.483027,"twenty":36.842143,"median":65.327391,"eighty":67.831007,"marketCap":611250000},{"date":"2021-09-10","current":66.285889,"twenty":36.842143,"median":65.39537,"eighty":67.784641,"marketCap":609437500},{"date":"2021-09-17","current":66.415048,"twenty":36.842143,"median":65.599305,"eighty":67.774619,"marketCap":610625000},{"date":"2021-09-24","current":66.34707,"twenty":36.842143,"median":65.599305,"eighty":67.706641,"marketCap":610000000},{"date":"2021-10-01","current":66.279091,"twenty":36.842143,"median":65.673742,"eighty":67.706641,"marketCap":609375000},{"date":"2021-10-08","current":66.34707,"twenty":36.879546,"median":65.735263,"eighty":67.638662,"marketCap":610000000},{"date":"2021-10-15","current":66.618984,"twenty":36.879546,"median":65.921864,"eighty":67.638662,"marketCap":612500000},{"date":"2021-10-22","current":66.143134,"twenty":36.879546,"median":65.939198,"eighty":67.638662,"marketCap":608125000},{"date":"2021-10-29","current":66.279771,"twenty":36.879546,"median":65.939198,"eighty":67.638662,"marketCap":609381250},{"date":"2021-11-05","current":66.754941,"twenty":36.879546,"median":65.939198,"eighty":67.570684,"marketCap":613750000},{"date":"2021-11-12","current":66.618984,"twenty":36.879546,"median":65.939198,"eighty":67.570684,"marketCap":612500000},{"date":"2021-11-19","current":66.618984,"twenty":36.879546,"median":65.939198,"eighty":67.502705,"marketCap":612500000},{"date":"2021-11-26","current":66.686962,"twenty":36.879546,"median":65.939198,"eighty":67.448322,"marketCap":613125000},{"date":"2021-12-03","current":66.618984,"twenty":36.879546,"median":65.984744,"eighty":67.434726,"marketCap":612500000},{"date":"2021-12-10","current":66.483027,"twenty":36.909812,"median":66.007177,"eighty":67.427112,"marketCap":611250000},{"date":"2021-12-17","current":66.211112,"twenty":36.97688,"median":66.007177,"eighty":67.411154,"marketCap":608750000},{"date":"2021-12-23","current":66.34707,"twenty":36.991756,"median":66.075155,"eighty":67.342317,"marketCap":610000000},{"date":"2021-12-31","current":66.143134,"twenty":37.014198,"median":66.143134,"eighty":67.298769,"marketCap":608125000},{"date":"2022-01-07","current":66.618984,"twenty":37.096484,"median":66.143134,"eighty":67.257982,"marketCap":612500000},{"date":"2022-01-14","current":66.143134,"twenty":37.161512,"median":66.143134,"eighty":67.108429,"marketCap":608125000},{"date":"2022-01-21","current":65.803241,"twenty":37.191435,"median":66.143134,"eighty":67.026855,"marketCap":605000000},{"date":"2022-01-28","current":65.803241,"twenty":37.216175,"median":66.143134,"eighty":67.026855,"marketCap":605000000},{"date":"2022-02-04","current":66.007177,"twenty":37.290981,"median":66.075155,"eighty":67.026855,"marketCap":606875000},{"date":"2022-02-11","current":66.007177,"twenty":37.506495,"median":66.075155,"eighty":66.999664,"marketCap":606875000},{"date":"2022-02-18","current":65.939198,"twenty":37.764475,"median":66.075155,"eighty":66.931685,"marketCap":606250000},{"date":"2022-02-25","current":66.007177,"twenty":38.188023,"median":66.041166,"eighty":66.890898,"marketCap":606875000},{"date":"2022-03-04","current":66.007177,"twenty":39.281235,"median":66.007177,"eighty":66.888686,"marketCap":606875000},{"date":"2022-03-11","current":66.279091,"twenty":39.349919,"median":66.041166,"eighty":66.87984,"marketCap":609375000},{"date":"2022-03-18","current":66.280451,"twenty":39.521628,"median":66.075155,"eighty":66.868456,"marketCap":609387500},{"date":"2022-03-25","current":66.34707,"twenty":40.225634,"median":66.075155,"eighty":66.816121,"marketCap":610000000},{"date":"2022-04-01","current":66.551005,"twenty":40.334382,"median":66.09215,"eighty":66.782132,"marketCap":611875000},{"date":"2022-04-08","current":66.551005,"twenty":40.609116,"median":66.143134,"eighty":66.754941,"marketCap":611875000},{"date":"2022-04-14","current":66.618984,"twenty":41.067006,"median":66.143134,"eighty":66.754941,"marketCap":612500000},{"date":"2022-04-22","current":66.686962,"twenty":41.210097,"median":66.143134,"eighty":66.754941,"marketCap":613125000},{"date":"2022-04-29","current":66.483027,"twenty":41.353188,"median":66.143134,"eighty":66.754941,"marketCap":611250000},{"date":"2022-05-06","current":66.551005,"twenty":41.639369,"median":66.143134,"eighty":66.754941,"marketCap":611875000},{"date":"2022-05-13","current":30.050032,"twenty":41.639369,"median":66.143134,"eighty":66.754941,"marketCap":610625000},{"date":"2022-05-20","current":29.927002,"twenty":40.494644,"median":66.143134,"eighty":66.754941,"marketCap":608125000},{"date":"2022-05-27","current":29.957759,"twenty":39.349919,"median":66.143134,"eighty":66.754941,"marketCap":608750000},{"date":"2022-06-03","current":29.957759,"twenty":37.609798,"median":66.143134,"eighty":66.754941,"marketCap":608750000},{"date":"2022-06-10","current":30.173062,"twenty":37.168227,"median":66.143134,"eighty":66.73422,"marketCap":613125000},{"date":"2022-06-17","current":30.050032,"twenty":36.97688,"median":66.143134,"eighty":66.72257,"marketCap":610625000},{"date":"2022-06-24","current":30.111547,"twenty":36.879546,"median":66.075155,"eighty":66.700558,"marketCap":611875000},{"date":"2022-07-01","current":30.111547,"twenty":36.879546,"median":66.075155,"eighty":66.686962,"marketCap":611875000},{"date":"2022-07-08","current":30.050032,"twenty":36.857104,"median":66.075155,"eighty":66.686962,"marketCap":610625000},{"date":"2022-07-15","current":30.050032,"twenty":36.842143,"median":66.041166,"eighty":66.686962,"marketCap":610625000},{"date":"2022-07-22","current":30.111547,"twenty":36.782298,"median":66.007177,"eighty":66.686962,"marketCap":611875000},{"date":"2022-07-29","current":30.111547,"twenty":36.685049,"median":66.007177,"eighty":66.686962,"marketCap":611875000},{"date":"2022-08-05","current":30.203819,"twenty":36.394254,"median":66.007177,"eighty":66.686962,"marketCap":613750000},{"date":"2022-08-12","current":30.203819,"twenty":35.543708,"median":66.007177,"eighty":66.686962,"marketCap":613750000},{"date":"2022-08-19","current":44.594207,"twenty":35.835613,"median":66.007177,"eighty":66.686962,"marketCap":612500000},{"date":"2022-08-26","current":44.639711,"twenty":36.201925,"median":66.007177,"eighty":66.686962,"marketCap":613125000},{"date":"2022-09-02","current":44.594207,"twenty":36.310674,"median":65.988823,"eighty":66.686962,"marketCap":612500000},{"date":"2022-09-09","current":44.616959,"twenty":36.369635,"median":65.96503,"eighty":66.686962,"marketCap":612812500},{"date":"2022-09-16","current":44.639711,"twenty":36.490553,"median":65.939198,"eighty":66.686962,"marketCap":613125000},{"date":"2022-09-23","current":44.685215,"twenty":36.595281,"median":65.939198,"eighty":66.673366,"marketCap":613750000},{"date":"2022-09-30","current":44.685215,"twenty":36.655127,"median":65.939198,"eighty":66.618984,"marketCap":613750000},{"date":"2022-10-07","current":44.867232,"twenty":36.670088,"median":65.939198,"eighty":66.618984,"marketCap":616250000},{"date":"2022-10-14","current":44.969617,"twenty":36.737414,"median":65.939198,"eighty":66.618984,"marketCap":617656250},{"date":"2022-10-21","current":45.049249,"twenty":36.767336,"median":65.939198,"eighty":66.618984,"marketCap":618750000},{"date":"2022-10-28","current":45.140258,"twenty":36.767336,"median":65.939198,"eighty":66.618984,"marketCap":620000000},{"date":"2022-11-04","current":45.185762,"twenty":36.774817,"median":65.939198,"eighty":66.618984,"marketCap":620625000},{"date":"2022-11-11","current":45.140713,"twenty":36.812221,"median":65.939198,"eighty":66.618984,"marketCap":620006250},{"date":"2022-11-18","current":33.101263,"twenty":36.737414,"median":65.888215,"eighty":66.618984,"marketCap":625000000},{"date":"2022-11-25","current":33.167465,"twenty":36.58032,"median":65.837231,"eighty":66.618984,"marketCap":626250000},{"date":"2022-12-02","current":33.233668,"twenty":36.144689,"median":65.803241,"eighty":66.618984,"marketCap":627500000},{"date":"2022-12-09","current":33.266769,"twenty":35.400618,"median":65.742061,"eighty":66.618984,"marketCap":628125000},{"date":"2022-12-16","current":33.266769,"twenty":34.828256,"median":65.735263,"eighty":66.618984,"marketCap":628125000},{"date":"2022-12-23","current":33.03506,"twenty":33.626294,"median":65.633634,"eighty":66.618984,"marketCap":623750000},{"date":"2022-12-30","current":33.167465,"twenty":33.311522,"median":65.599305,"eighty":66.618984,"marketCap":626250000},{"date":"2023-01-06","current":33.051611,"twenty":33.266769,"median":65.599305,"eighty":66.618984,"marketCap":624062500},{"date":"2023-01-13","current":33.001959,"twenty":33.253529,"median":65.39537,"eighty":66.618984,"marketCap":623125000},{"date":"2023-01-20","current":33.167465,"twenty":33.193218,"median":65.327391,"eighty":66.618984,"marketCap":626250000},{"date":"2023-01-27","current":33.233668,"twenty":33.167465,"median":63.147538,"eighty":66.618984,"marketCap":627500000},{"date":"2023-02-03","current":33.134364,"twenty":33.167465,"median":61.828037,"eighty":66.618984,"marketCap":625625000},{"date":"2023-02-10","current":33.134364,"twenty":33.147604,"median":60.546236,"eighty":66.618984,"marketCap":625625000},{"date":"2023-02-17","current":33.399174,"twenty":33.167465,"median":58.284235,"eighty":66.618984,"marketCap":630625000},{"date":"2023-02-24","current":33.233668,"twenty":33.167465,"median":57.304034,"eighty":66.618984,"marketCap":627500000},{"date":"2023-03-03","current":33.332971,"twenty":33.167465,"median":56.983584,"eighty":66.605388,"marketCap":629375000},{"date":"2023-03-10","current":33.29987,"twenty":33.167465,"median":55.720633,"eighty":66.551005,"marketCap":628750000},{"date":"2023-03-17","current":33.366073,"twenty":33.167465,"median":54.778133,"eighty":66.551005,"marketCap":630000000},{"date":"2023-03-24","current":33.233999,"twenty":33.167465,"median":54.174932,"eighty":66.551005,"marketCap":627506250},{"date":"2023-03-31","current":33.399174,"twenty":33.167465,"median":53.477482,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-06","current":33.332971,"twenty":33.167465,"median":53.251282,"eighty":66.551005,"marketCap":629375000},{"date":"2023-04-14","current":33.399174,"twenty":33.184016,"median":52.591531,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-21","current":33.399174,"twenty":33.188319,"median":51.931781,"eighty":66.551005,"marketCap":630625000},{"date":"2023-04-28","current":26.2563,"twenty":33.167465,"median":51.083531,"eighty":66.551005,"marketCap":629375000},{"date":"2023-05-05","current":26.2563,"twenty":33.167465,"median":50.78193,"eighty":66.551005,"marketCap":629375000},{"date":"2023-05-12","current":26.334521,"twenty":33.134364,"median":50.51803,"eighty":66.551005,"marketCap":631250000},{"date":"2023-05-19","current":51.891527,"twenty":33.134364,"median":50.63113,"eighty":66.551005,"marketCap":630937500},{"date":"2023-05-26","current":11.488324,"twenty":33.134364,"median":50.89503,"eighty":66.489825,"marketCap":139683972},{"date":"2023-06-02","current":11.522516,"twenty":33.134364,"median":50.59343,"eighty":66.484387,"marketCap":140099699},{"date":"2023-06-09","current":11.522516,"twenty":33.101263,"median":50.25413,"eighty":66.483027,"marketCap":140099699},{"date":"2023-06-16","current":11.522516,"twenty":33.064851,"median":49.160829,"eighty":66.483027,"marketCap":140099699},{"date":"2023-06-23","current":11.533913,"twenty":33.051611,"median":48.972329,"eighty":66.483027,"marketCap":140238274},{"date":"2023-06-30","current":11.556707,"twenty":33.049625,"median":47.879029,"eighty":66.483027,"marketCap":140515425},{"date":"2023-07-07","current":11.556707,"twenty":33.03506,"median":46.790631,"eighty":66.483027,"marketCap":140515425},{"date":"2023-07-14","current":11.619619,"twenty":33.008579,"median":46.295628,"eighty":66.483027,"marketCap":141280361},{"date":"2023-07-21","current":11.619619,"twenty":32.935756,"median":45.880927,"eighty":66.483027,"marketCap":141280361},{"date":"2023-07-28","current":11.659281,"twenty":32.869554,"median":45.185762,"eighty":66.483027,"marketCap":141762603},{"date":"2023-08-04","current":11.659281,"twenty":32.720598,"median":45.185762,"eighty":66.483027,"marketCap":141762603},{"date":"2023-08-11","current":11.647998,"twenty":30.203819,"median":45.185762,"eighty":66.483027,"marketCap":141625413},{"date":"2023-08-18","current":18.12164,"twenty":30.173062,"median":45.140258,"eighty":66.483027,"marketCap":142316904},{"date":"2023-08-25","current":18.174576,"twenty":30.142304,"median":45.128882,"eighty":66.483027,"marketCap":142732631},{"date":"2023-09-01","current":18.262625,"twenty":30.117698,"median":45.094754,"eighty":66.483027,"marketCap":143424122},{"date":"2023-09-08","current":18.262802,"twenty":30.111547,"median":45.094754,"eighty":66.483027,"marketCap":143425507},{"date":"2023-09-14","current":18.280447,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":143564083},{"date":"2023-09-22","current":18.52748,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":145504138},{"date":"2023-09-29","current":18.368673,"twenty":30.111547,"median":45.049249,"eighty":66.483027,"marketCap":144256960},{"date":"2023-10-06","current":18.403963,"twenty":30.080789,"median":44.969617,"eighty":66.483027,"marketCap":144534110},{"date":"2023-10-13","current":18.392494,"twenty":30.080789,"median":44.889984,"eighty":66.483027,"marketCap":144444036},{"date":"2023-10-20","current":18.351028,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":144118384},{"date":"2023-10-27","current":18.351204,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":144119770},{"date":"2023-11-03","current":18.368673,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":144256960},{"date":"2023-11-10","current":18.368673,"twenty":30.050032,"median":44.707967,"eighty":66.483027,"marketCap":144256960},{"date":"2023-11-17","current":18.298269,"twenty":30.032869,"median":44.696591,"eighty":66.483027,"marketCap":143704044},{"date":"2023-11-24","current":54.096492,"twenty":30.050032,"median":44.707967,"eighty":66.483027,"marketCap":140873053},{"date":"2023-11-30","current":54.200624,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":141144224},{"date":"2023-12-22","current":54.096492,"twenty":30.050032,"median":44.730719,"eighty":66.483027,"marketCap":140873053},{"date":"2023-12-29","current":54.25269,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":141279809},{"date":"2024-01-05","current":54.25269,"twenty":30.050032,"median":44.776224,"eighty":66.483027,"marketCap":141279809},{"date":"2024-01-12","current":54.513019,"twenty":30.050032,"median":44.889984,"eighty":66.428644,"marketCap":141957735},{"date":"2024-01-19","current":54.513019,"twenty":30.050032,"median":44.963929,"eighty":66.415048,"marketCap":141957735},{"date":"2024-01-26","current":54.877481,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-02","current":54.877481,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-09","current":54.513019,"twenty":30.050032,"median":45.049249,"eighty":66.415048,"marketCap":141957735},{"date":"2024-02-16","current":54.773349,"twenty":30.050032,"median":45.094754,"eighty":66.415048,"marketCap":142635661},{"date":"2024-02-23","current":54.877481,"twenty":30.050032,"median":45.128882,"eighty":66.415048,"marketCap":142906832},{"date":"2024-02-28","current":54.877481,"twenty":30.050032,"median":45.140258,"eighty":66.415048,"marketCap":142906832}],"updateTime":1761856910593},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LCA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579929415","title":"Bureau Veritas Showcases Three Key Net-Zero Transformation Solutions at Energy Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2579929415","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579929415?lang=en_us&edition=fundamental","pubTime":"2025-10-29 15:32","pubTimestamp":1761723120,"startTime":"0","endTime":"0","summary":"TAIPEI, Oct. 29, 2025 /PRNewswire/ --As one of the world's leading testing, inspection, and certification companies, Bureau Veritas  will participate in Energy Taiwan 2025, organized by SEMI and the Taiwan External Trade Development Council . This year's exhibition, themed \"Towards Net-Zero Taiwan,\" will take place from October 29 to 31 at Taipei Nangang Exhibition Center, Hall 1 .During the exhibition, BV will highlight its comprehensive solutions under the three key pillars of net-zero transformation — New Energy, Sustainability, and Cybersecurity — demonstrating BV's strong capabilities in supporting global green transition and sustainable development.As smart manufacturing and IoT applications continue to expand, BV provides comprehensive cybersecurity testing and certification services, including product security testing, penetration testing, and information security & AI management system . These services help enterprises str","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2808071/Bureau_Veritas.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2808071/Bureau_Veritas.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/bureau-veritas-showcases-three-key-net-zero-transformation-solutions-at-energy-taiwan-302598082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","LCA","CPS","BK4120","BV"],"gpt_icon":0},{"id":"2575529055","title":"Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575529055","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575529055?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Oct.  14, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166083/0/en/Opus-Genetics-to-Participate-in-Chardan-s-9th-Annual-Genetic-Medicines-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","MDCO"],"gpt_icon":0},{"id":"2572514715","title":"Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514715","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514715?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:00","pubTimestamp":1759406400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Oct.  02, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/02/3160325/0/en/Opus-Genetics-to-Present-at-Upcoming-Medical-and-Industry-Conferences-in-October-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2571034156","title":"Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571034156","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571034156?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230000,"startTime":"0","endTime":"0","summary":"Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses obse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/30/3158427/0/en/Opus-Genetics-Reports-Positive-Pediatric-Data-from-OPGx-LCA5-Phase-1-2-Trial-in-Leber-Congenital-Amaurosis-Type-5-LCA5.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2571725848","title":"Envision Energy Earns \"Green Passport\" EPD, Raising the Benchmark for Sustainable Wind Turbines","url":"https://stock-news.laohu8.com/highlight/detail?id=2571725848","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571725848?lang=en_us&edition=fundamental","pubTime":"2025-09-29 10:41","pubTimestamp":1759113660,"startTime":"0","endTime":"0","summary":"MILAN, Sept. 29, 2025 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced that its key wind turbine models, the EN-171/6.0/6.25/6.5 and EN-182/6.25, have been published the Environmental Product Declaration  on EPDItaly platform. This achievement highlights Envision Energy's sustainability leadership and provides internationally recognized green credentials for customers and partners, helping shift the industry from pure price competition to full life-cycle environmental value competition, paving the way for a greener future.Digital Carbon Management Tools: Envision Energy has created a digital energy and carbon management platform covering global sites, major products, and core supply chains. This time, we utilized the carbon accounting and life cycle assessment  pl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/envision-energy-earns-green-passport-epd-raising-the-benchmark-for-sustainable-wind-turbines-302569116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1150488218.USD","LU1150488135.SGD","LCA","BK4588","BK4561","EPD.AU","AP","BK4585","EP","BK4213","BK4590","EPD","BK4006","BK4144"],"gpt_icon":0},{"id":"2566979961","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566979961","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566979961?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:00","pubTimestamp":1757678400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept.  12, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/12/3149159/0/en/Opus-Genetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","NVIW.SI","IE00BGHQF748.EUR","TSYW.SI","LU0314104364.USD","PSQ","QLD","LU2095319765.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","TQQQ","MNQmain","BK4112",".IXIC","LU2210149790.SGD","SQQQ","USAW.SI","IE00BKPKM429.USD","LCA","BK4588","USJW.SI","QID","BK4585","NDAQ"],"gpt_icon":1},{"id":"2564712323","title":"Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2564712323","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564712323?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:00","pubTimestamp":1756987200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept.  04, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal disease","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/04/3144432/0/en/Opus-Genetics-Doses-First-Patient-in-Pivotal-LYNX-3-Phase-3-Trial-Evaluating-Phentolamine-Ophthalmic-Solution-0-75-in-Keratorefractive-Patients-With-Visual-Disturbances-Under-Mesop.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","BK4211","PRK"],"gpt_icon":0},{"id":"2564913804","title":"Press Release: Opus Genetics Appoints Rob Gagnon as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564913804","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564913804?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:00","pubTimestamp":1756814400,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025  -- Opus Genetics, Inc. , a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases  and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer.Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A.Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases  and small molecule therapies for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital am","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD","LCA"],"gpt_icon":0},{"id":"2562746647","title":"Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2562746647","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562746647?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296000,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Aug.  27, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139962/0/en/Opus-Genetics-Inherited-Retinal-Disease-Programs-Featured-at-Medical-and-Industry-Conferences-in-September.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2560074902","title":"Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1","url":"https://stock-news.laohu8.com/highlight/detail?id=2560074902","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560074902?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518400,"startTime":"0","endTime":"0","summary":"– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug.  18, 2025  (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/18/3134953/0/en/Opus-Genetics-Announces-FDA-Clearance-of-IND-Application-for-Gene-Therapy-Candidate-OPGx-BEST1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2559981194","title":"Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981194","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981194?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:30","pubTimestamp":1755117000,"startTime":"0","endTime":"0","summary":"- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Adv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3133018/0/en/Opus-Genetics-Announces-Financial-Results-for-Second-Quarter-2025-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721427968.SGD","LCA","BK4086","LU2413666004.HKD","AOS","LU2380233275.USD","LU1165135440.EUR","LU1543694498.USD","LU1620156130.USD","LU1620156213.USD","LU1596574779.USD","LU2413665964.HKD","BK4588","BK4585"],"gpt_icon":0},{"id":"2557911993","title":"Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2557911993","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557911993?lang=en_us&edition=fundamental","pubTime":"2025-08-05 20:00","pubTimestamp":1754395200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., Aug.  05, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/05/3127277/0/en/Opus-Genetics-to-Participate-in-the-H-C-Wainwright-5th-Annual-Ophthalmology-Virtual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2553248808","title":"Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness","url":"https://stock-news.laohu8.com/highlight/detail?id=2553248808","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553248808?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:00","pubTimestamp":1753272000,"startTime":"0","endTime":"0","summary":"Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July  23, 2025  (GLOBE NEWSWIRE) --","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/23/3120191/0/en/Opus-Genetics-and-the-Global-RDH12-Alliance-Partner-to-Advance-RDH12-Gene-Therapy-for-Inherited-Childhood-Blindness.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA"],"gpt_icon":0},{"id":"2548107387","title":"Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548107387","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548107387?lang=en_us&edition=fundamental","pubTime":"2025-07-04 04:30","pubTimestamp":1751574600,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., July  03, 2025  (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/03/3110111/0/en/Opus-Genetics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","IE00BGHQF748.EUR","QID","TQQQ","BK4588","USJW.SI","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","LU2210149790.SGD","NVIW.SI",".IXIC","QLD","PSQ","BK4112","TSYW.SI","USAW.SI","IE00B64PRP62.GBP","LU2095319765.USD","MNQmain","IE00BKPKM429.USD","LCA","SQQQ","BK4585"],"gpt_icon":1},{"id":"2545419232","title":"Press Release: Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419232?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680000,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., June 23, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases  and small molecule therapies for other ophthalmic disorders, recently disclosed that the Retinal Degeneration Fund , the venture philanthropy arm of the Foundation Fighting Blindness, has entered into a funding agreement with Opus providing for up to $2 million in non-dilutive funding intended to support the advancement of Opus' OPGx-MERTK program to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosine kinase  gene.\"This strategic funding enables us to advance the development of OPGx-MERTK, a promising program that aims to address a retinal degenerative condition with no currently approved therapies,\" said George Magrath, M.D., CEO, Opus Genetics. \"OPGx-MERTK is currently in preclinical development, and we","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007","LCA"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}